Business Wire

Lobe Sciences Initiates Phase 1 Clinical Trial of L-130

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to dateVANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a

More

Anaergia Appoints Deloitte LLP as Auditor

BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG), a global renewable fuels leader, announced that Deloitte LLP (“Deloitte”) has been retained by the Company to be its auditor. Deloitte has taken ove

More

Jubilant Radiopharma Introduces RUBY Mobile Solutions™

MONTREAL--(BUSINESS WIRE)--Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 g

More